# EDGAR Filing Document

**Accession Number:** 0002029039
**File Stem:** 0001493152-25-011753
**Filing Date:** 2025-8
**Character Count:** 4361
**Document Hash:** 2c11196449b4af5a4a0fb456923a3238
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-011753.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001493152-25-011753

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nasus Pharma Ltd
- **CENTRAL INDEX KEY:** 0002029039
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 516022712
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42796
- **FILM NUMBER:** 251198595

**BUSINESS ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003
- **BUSINESS PHONE:** 972 54-255-3956

**MAIL ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**

**PURSUANT TO SECTION 12(b) OR (g) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**NASUS PHARMA LTD.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **State of Israel** | **Not Applicable** |
| (State of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **Yigal Alon 65**<br> **Tel Aviv, Israel** | **6744317** |
| (Address of principal executive offices) | (Zip Code) |

---

Securities to be registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class<br> to be so registered** | **Name of each exchange on which<br> each class is to be registered** |
| **Ordinary Shares, no par value** | **NYSE American, LLC** |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates:

**333-288582**

Securities to be registered pursuant to Section 12(g) of the Act:

**None**

**Item 1. Description of Registrant's Securities to be Registered.**

Nasus Pharma Ltd. (the "***Registrant***") hereby incorporates by reference (a) the description of its ordinary shares, no par value ("***Ordinary Shares***") to be registered hereunder under the heading "Description of Share Capital and Governing Documents" and (b) the information set forth under the heading "Taxation," each in the Registrant's Registration Statement on Form F-1 (File No. 333-288582) initially filed with the Securities and Exchange Commission (the "***Commission***") on July 9, 2025 (and as subsequently amended and supplemented, the "***Registration Statement***"), and any prospectus that constitutes part of the Registration Statement and that is subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which information shall be deemed to be incorporated herein by reference.

**Item 2. Exhibits.**

Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on NYSE American, LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **Nasus Pharma Ltd.** | **Nasus Pharma Ltd.** |
| Date: | August 8, 2025 | By: | */s/ Dan Teleman* |
|  |  |  | Dan Teleman |
|  |  |  | Chief Executive Officer |

---